Photocure Asa

OSLO, Norway, September 27, 2011 - Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world except Nordics and the US Photocure to commercialise the product directly in the US market Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today the execution of a new commercial strategy for Hexvix, its flagship product to aid in diagnosing bladder cancer.